Posted by Bob on April 15, 2002, at 16:19:27
In reply to Re: New Antidepressants in Development?, posted by zero on April 15, 2002, at 13:31:16
Boy! Looking at this list below is kind of frustrating. There aren't many truly novel drugs in phase III; most of them are in the earlier phases. I suspect this is because they get weeded out by the time they get to phase III. Also, it annoys me how long something takes to come to market, even when it does pass phase III. I think it is typically 1 to 2 years. What a waiting game!!!
> (hope this long list is informative - zero)
> CenterWatch's comprehensive Directory of Drugs in Clinical Trials:
>
>
> Company Name Trade Name Generic Name Condition(s), Phase(s)
>
> GlaxoSmithKline Paxil, Seroxat paroxetine Depression, III
>
> Yamanouchi Pharmaceutical N/A YM-992 Depression, II
>
> Wyeth Research Effexor XR venlafaxine HCl Depression, FDA approved
>
> Janssen Pharmaceutica N/A YKP-10A Depression, IIa completed
>
> Merck N/A substance P antagonist candidates Depression, IIa
>
> Merck N/A MK-869 Depression, III
> Cephalon Provigil modafinil Depression, II
>
> Boehringer Ingelheim N/A flibanserin Depression, II
>
> Merck KgaA N/A anti-depressant Depression, II
> Sanofi-Synthelabo Pharmaceuticals N/A SR 58611 Depression, II b
>
> Eli Lilly N/A duloxetine HCl, LY-248686 Depression, NDA submitted
>
> Innapharma N/A INN-00835 Depression, II completed
>
> NeuroSearch A/S N/A NS-2389 Depression, II
>
> Eli Lilly Zyprexa olanzapine Depression, III
>
> Neurocrine Biosciences N/A NBI-34041 Depression, I
>
> NPS Pharmaceuticals N/A NPS 1506 Depression, Ib completed
>
> Kyowa Hakko N/A KW-6002 Depression, II
>
> Forest Laboratories N/A escitalopram Depression, NDA submitted
>
> AstraZeneca N/A robalzotan, NAD 299 Depression, II
>
> Solvay Pharmaceuticals N/A SLV 308 Depression, II
>
> Takeda Chemical Industries N/A TAK-637 Depression, II
>
> Organon Ariza 5HT-1A partial agonist Depression, III
>
> Annovis N/A amino-cyclopropane carboxylic acid Depression, I
>
> GlaxoSmithKline N/A GW 597599 Depression, I
>
> GlaxoSmithKline N/A SB 243213 Depression, Discontinued
>
> GlaxoSmithKline N/A SB 659746A, EMD 68843 Depression, II
>
> GlaxoSmithKline N/A GW 650250 Depression, II
>
> Janssen Pharmaceutica N/A R 107474 Depression, Discontinued
>
> Janssen Pharmaceutica N/A CRF receptor antagonist, NBI-37582 Depression, I
>
> Pfizer N/A NGD 98-1 Depression, II
>
> Eli Lilly Prozac Weekly fluoxetine HCI Depression, FDA approved
>
> Eli Lilly Prozac fluoxetine HCl Depression, FDA approved
>
> Eli Lilly N/A Olanzapine-fluoxetine combination Depression, III
>
> Fabre-Kramer Pharmaceuticals N/A gepirone Depression, III completed
>
> Pfizer N/A JO-1784, CI-1019 Depression, Discontinued
>
> Dainippon Pharmaceutical N/A moclobemide Depression, II
>
> Pfizer N/A CP-122,721 Depression, II
>
> Hoffmann-La Roche N/A NK-1 Depression, I
>
> Otsuka America Pharmaceutical N/A OPC-14523 Depression, II
>
> Organon N/A ORG-12962 Depression, II
>
> Cortex Pharmaceuticals N/A ORG-24448, CX-619 Depression, I
>
> Organon N/A ORG-34167 Depression, I
>
> Organon N/A ORG-34517 Depression, II
>
> Pharmacia Vestra reboxetine Depression, FDA denied
>
> Mitsubishi Chemical Corporation N/A MCI-225 Depression, II
>
> Somerset Pharmaceuticals Emsam selegiline Depression, NDA denied
>
> GlaxoSmithKline N/A SB723620 Depression, I
>
> Sepracor N/A (R)-sibutramine metabolite Depression, II
poster:Bob
thread:103083
URL: http://www.dr-bob.org/babble/20020408/msgs/103156.html